文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

多黏菌素B为基础联合方案治疗ICU脓毒症伴广泛耐药革兰阴性菌感染的临床分析

[Clinical analysis of sepsis with extensively drug resistant Gram-negative bacteria in intensive care unit treated with polymyxin B-based combination therapy].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论回顾性分析显示多黏菌素B为基础联合方案治疗ICU广泛耐药革兰阴性菌脓毒症微生物清除率65.2%、总体有效率59.0%、28天全因死亡率41.0%。

该研究回顾性分析2018年6月至2019年9月中南大学湘雅医院重症医学科39例接受多黏菌素B治疗的广泛耐药革兰阴性菌感染脓毒症患者。主要感染部位为肺部(51.2%),检出病原菌66株,以鲍曼不动杆菌检出率最高(51.5%)。多黏菌素B治疗后微生物清除率65.2%、总体有效率59.0%、28天全因死亡率41.0%;日剂量150 mg和200 mg组有效率和微生物清除率均高于100 mg组。4例肾损伤患者用药期间血肌酐升高,停药后恢复。

要点

  • 39例广泛耐药革兰阴性菌脓毒症患者接受多黏菌素B为基础联合治疗,总体有效率59.0%(23/39),28天全因死亡率41.0%(16/39)。
  • 日剂量150 mg组和200 mg组有效率分别为85.7%(6/7)和87.5%(7/8),均高于100 mg组的41.7%(10/24),差异有统计学意义(均P<0.05)。
  • 日剂量150 mg组和200 mg组微生物清除率分别为71.4%(5/7)和87.5%(7/8),均高于100 mg组的33.3%(8/24),差异有统计学意义(均P<0.05)。
  • 不同疗程组(<10天、10-15天、>15天)有效率和微生物清除率无显著差异(P=0.728和P=0.393)。
  • 4例肾损伤患者用药期间血清肌酐升高,停药后恢复,未见其他不良反应。

适用人群与场景

  • 2018年6月至2019年9月中南大学湘雅医院重症医学科收治的广泛耐药革兰阴性菌感染脓毒症患者39例,男32例(82.1%),平均年龄(53.6±12.6)岁。
  • 主要感染部位为肺部感染(51.2%),多黏菌素B疗程≥5天。

处置流程与药物剂量

  • 多黏菌素B为基础联合治疗方案,日剂量分为100 mg、150 mg、200 mg组,疗程≥5天。
  • 日剂量150 mg和200 mg组有效率和微生物清除率均显著高于100 mg组(均P<0.05)。

研究设计与关键结果

  • 回顾性分析39例广泛耐药革兰阴性菌脓毒症患者,共检出病原菌66株,鲍曼不动杆菌检出率最高为51.5%(34/66)。
  • 多黏菌素B治疗后微生物清除率65.2%(43/66),总体有效率59.0%(23/39),28天全因死亡率41.0%(16/39)。
  • 不同疗程组(<10天、10-15天、>15天)有效率分别为56.5%(13/23)、54.5%(6/11)、80.0%(4/5),差异无统计学意义(χ²=0.999,P=0.728);微生物清除率分别为43.5%(10/23)、54.5%(6/11)、80.0%(4/5),差异无统计学意义(χ²=2.141,P=0.393)。
  • 日剂量100 mg组、150 mg组、200 mg组有效率分别为41.7%(10/24)、85.7%(6/7)、87.5%(7/8),150 mg组和200 mg组均高于100 mg组(均P<0.05);微生物清除率分别为33.3%(8/24)、71.4%(5/7)、87.5%(7/8),150 mg组和200 mg组均高于100 mg组(均P<0.05)。
  • 不同日剂量组ICU住院时间和机械通气时间无显著差异。
  • 多黏菌素B给药后APACHEⅡ评分显著低于给药前(全部患者:16.20±9.24 vs. 24.40±4.73,有效患者:11.30±4.08 vs. 23.00±4.56,均P<0.05)。
  • 4例肾损伤患者用药期间血清肌酐升高,停药后恢复,无其他不良反应。

证据类型、等级与局限

  • 证据类型:回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为多黏菌素B可作为广泛耐药革兰阴性菌严重感染患者的有效治疗选择。
  • 日剂量150 mg和200 mg组有效率和微生物清除率均高于100 mg组,但不同日剂量组ICU住院时间和机械通气时间无显著差异。
  • 用药期间需注意肾损伤患者血清肌酐升高,停药后可恢复。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the clinical efficacy and safety of polymyxin B in the treatment of sepsis caused by extensively-drug resistant (XDR) Gram-negative bacteria.

METHODS: A retrospective analysis of 39 septic patients with XDR Gram-negative bacterial infection treated with polymyxin B in the department of critical care medicine of Xiangya Hospital of Central South University from June 2018 to September 2019 were enrolled. The clinical characteristics, bacterial culture, the sensitivity antibacterial drugs, types and courses of antibiotics, biochemical indexes, and acute physiology and chronic health evaluation II (APACHE II) before and after polymyxin B treatment were collected, to assess microbial clearance and efficacy, drug related adverse effects, and 28-day mortality in septic patients with XDR.

RESULTS: Of the 39 septic patients with XDR, 32 (82.1%) were male, with the mean age of (53.6±12.6) years old. The main infection site was pulmonary infection (51.2%), and the treatment courses of polymyxin B were ≥ 5 days. A total of 66 pathogenic bacteria were detected from 39 patients. Among them, with the high estrate of detecting Acinetobacter baumannii of 51.5% (34/66). After treatment with polymyxin B, the results showed that the clearance rate of microorganisms was 65.2% (43/66), the overall effective rate was 59.0% (23/39), and the 28-day all-cause mortality was 41.0% (16/39). There were no significant differences in clinical efficacy and microbial clearance among patients with different treatment groups of polymyxin B [< 10 days, 10-15 days, and > 15 days groups: effective rates were 56.5% (13/23), 54.5% (6/11), 80.0% (4/5), χ 2 = 0.999, P = 0.728; the microbial clearance rates were 43.5% (10/23), 54.5% (6/11), and 80.0% (4/5), χ 2 = 2.141, P = 0.393]. The effective and microbial clearance rates of the polymyxin B daily doses of 150 mg and 200 mg groups were significantly higher than those of the daily dose of 100 mg [effectiveness: 85.7% (6/7), 87.5% (7/8) vs. 41.7% (10/24); microbial clearance rate: 71.4% (5/7), 87.5% (7/8) vs. 33.3% (8/24), all P < 0.05], however, there were no significant differences in the length of intensive care unit (ICU) stay and mechanical ventilation time among different daily dose groups. The APACHE II score after polymyxin B administration was significantly lower than before administration (all patients: 16.20±9.24 vs. 24.40±4.73, effective patients: 11.30±4.08 vs. 23.00±4.56, both P < 0.05). Four patients with renal injury had an increase in serum creatinine during the administration of polymyxin B, and recovered after discontinuation of the drug without other adverse reactions.

CONCLUSIONS: Polymyxin B can be used as an effective treatment option for patients with severe infection of XDR Gram-negative bacteria.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhao S, Yan L, Wang C, et al. [Clinical analysis of sepsis with extensively drug resistant Gram-negative bacteria in intensive care unit treated with polymyxin B-based combination therapy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32274997. doi:10.3760/cma.j.cn121430-20200108-00028

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。